Cefurim

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefurim

Property Description
Active ingredient Cefuroxime (as Axetil or Sodium)
Form Tablet, Oral Suspension, Powder for Injection/Infusion
Pharmacological class Second-Generation Cephalosporin Antibiotic
Common use Treatment of bacterial infections (broad-spectrum)
Origin Semisynthetic beta-lactam agent

Defining Cefurim: Its Pharmacological Class and Purpose

Cefurim is a semisynthetic beta-lactam antibiotic whose active pharmaceutical ingredient is Cefuroxime, classified as a second-generation cephalosporin. The medicine is a broad-spectrum agent designed to eliminate a wide array of harmful bacterial infections within the body.

The classification as a second-generation cephalosporin signifies that Cefuroxime is versatile, often used to clear pathogens responsible for respiratory or urinary tract infections. Its bactericidal effect actively kills susceptible pathogens by interfering with the synthesis of the protective cell wall structure.


Composition and Available Forms of Cefuroxime

The core composition relies solely on Cefuroxime, making it a single-ingredient product, supplied primarily as the injectable Cefuroxime Sodium and the oral Cefuroxime Axetil. This allows for administration via the oral, intravenous (IV), and intramuscular (IM) routes.

The oral version, Cefuroxime Axetil, is a prodrug administered as a tablet or suspension that must be rapidly broken down into the active Cefuroxime substance. This design feature ensures effective drug absorption through the digestive tract.


How Cefurim Differs from Older Antibiotics

As a second-generation beta-lactam agent, Cefurim holds a key advantage in therapeutic efficacy by demonstrating enhanced stability against beta-lactamase enzymes. These enzymes, produced by certain bacteria, can inactivate older antibiotic classes through chemical breakdown. This inherent beta-lactamase resistance is a property of Cefuroxime, securing its function as a broad-spectrum antibiotic capable of combating resistant pathogens.

Regulatory References

  1. Cefuroxime - StatPearls - NIH

What side effects are possible with Cefurim?

Possible side effects and safety information

Cefurim (Cefuroxime) is associated with adverse reactions that are classified by regulatory authorities based on the affected body system and reported frequency.

Adverse effects are formally categorized within system-organ classes, with commonly reported events affecting the Gastrointestinal System and Blood and Lymphatic System.

Officially Classified Frequencies

Classification Examples of Documented Reactions
Common (1/10 to 1/100) Candidiasis, Eosinophilia, Headache, Dizziness, Diarrhea, Nausea, transient increase in liver enzyme levels
Uncommon (1/100 to 1/1,000) Positive Coombs test, Leukopenia, Thrombocytopenia, Vomiting, Skin rash, Urticaria

Serious adverse reactions, though classified as rare or very rare, are documented in regulatory labeling. These include life-threatening Anaphylactic Reactions, severe skin disorders such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and Pseudomembranous Colitis (Clostridioides difficile-associated diarrhea). Seizures have been reported, particularly when high doses are administered to individuals with renal impairment.

Specific safety considerations are defined for certain populations. Since Cefuroxime is primarily eliminated by the kidneys, patients with marked renal impairment require a dosage modification to limit the risk of neurotoxicity. Furthermore, safety documentation notes that the onset of severe gastrointestinal effects like colitis can occur not only during treatment but also up to two or more months after therapy has ceased.

Cefurim is contraindicated in patients with a history of severe hypersensitivity to any cephalosporin or other beta-lactam antibacterial drug. The medicine can also interfere with certain laboratory tests, potentially causing a false-positive result for urine glucose with copper reduction methods and a positive Coombs test.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

The regulatory guidance for Cefurim (Cefuroxime) overdose defines specific, severe manifestations that necessitate immediate medical intervention. Officially documented overdose presentations primarily involve the Central Nervous System (CNS), with the potential for seizures and subsequent signs of cerebral irritation. These neurological effects are categorized as life-threatening outcomes if they escalate to clinical signs such as collapse, significant trouble breathing, or the inability to be awakened (loss of consciousness).

Regulatory documents establish clear emergency response statements. Immediate medical help must be sought if any severe sign—such as a seizure, collapse, or trouble breathing—is observed. In these scenarios, the official instruction is to call emergency services (911) or contact a regional poison control helpline.

Management and Population Considerations

Management procedures are defined as symptomatic and supportive treatment, as regulatory information states that no specific antidote is known. Documented measures for reducing high systemic concentrations of the drug include procedural interventions such as hemodialysis or peritoneal dialysis. A specific consideration noted in official prescribing information is that the risk of overdose effects may be augmented in patients with impaired renal function due to reduced drug clearance, necessitating caution in this population.

Therapeutic Uses of Cefurim

What Cefurim Treats: Main Uses and Benefits

Cefurim (Cefuroxime) is a second-generation cephalosporin antibiotic generally used to address susceptible bacterial infections across multiple body systems, supporting the management of symptoms. Its use is generally considered relevant in clinical settings that involve acute or unstable symptom patterns caused by susceptible bacteria.

This medication is commonly applied in conditions characterized by periods of heightened symptoms such as acute bacterial sinusitis, pneumonia, uncomplicated urinary tract infections (UTIs), and skin and soft tissue infections like cellulitis. It is also used across domains where additional symptomatic support is needed for infections of the ear, throat, and tonsils, as well as in more severe contexts like septicemia and Early Lyme Disease. Cefurim provides support that generally helps ease localized discomfort and may contribute to supporting day-to-day comfort during these highly symptomatic periods. Its use offers symptomatic relief that helps patients cope more steadily with difficult episodes.

“The therapeutic intent is to support the patient during episodes of heightened discomfort and assist with maintaining functional stability.”


Quick Fact: Relief for Localized Discomfort

Cefurim is commonly used when symptoms cluster into patterns that interfere with daily comfort, particularly for sore throat, ear pain (otalgia), facial pressure, and painful or frequent urination (dysuria). It is often applied in scenarios where short-term symptomatic assistance is needed.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is contraindicated include individuals with a known hypersensitivity to the active ingredient, cefuroxime, or to any other cephalosporin antibiotic. This absolute prohibition extends to patients with a history of a severe allergic reaction to any beta-lactam antibacterial drug, such as penicillin.

Age-related eligibility is established for adults and adolescents. Pediatric use is approved for patients aged three months and older for the oral suspension; however, safety has not been established for infants under three months of age. The oral tablet is not suitable for young children who cannot swallow the tablet whole.

Condition-specific eligibility rules require caution or restriction for certain populations. Patients with impaired renal function require close monitoring and a mandatory dose adjustment to compensate for slower drug excretion. The oral suspension is not recommended for patients with Phenylketonuria (PKU) because the formulation contains phenylalanine. Use is also generally not recommended in the presence of severe vomiting or diarrhea.

Pregnancy and lactation eligibility is restricted. Use during pregnancy is permitted only when the likely benefit clearly outweighs the potential risk due to limited human data. Caution is also necessary during lactation, as cefuroxime is known to be excreted into human milk in small quantities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cefurim, a cephalosporin antibiotic, has specific documented interactions with certain medicinal products and substance categories based on regulatory information. It is important to discuss all concurrent medications with a healthcare professional.

Interacting Medicinal Products and Categories:

Interacting Product/Category Mechanism and Outcome Classification
Probenecid (Uricosurics) This drug inhibits the active renal tubular secretion of Cefurim, leading to increased and prolonged plasma concentrations of the antibiotic. This interaction is pharmacokinetic. Use with caution; monitor for toxicity
Combined Oral Contraceptives The potential exists for this antibiotic to reduce the efficacy of the oral contraceptive. The mechanism is historically linked to the disruption of the enterohepatic circulation of the estrogen component, posing a risk of therapeutic failure (unintended pregnancy). Clinically significant potential interaction

Co-administration with Probenecid requires consideration for dosage adjustment to prevent excessive Cefurim exposure. Although scientific consensus for most non-enzyme-inducing antibiotics suggests minimal risk to combined hormonal contraceptive efficacy, official labeling includes a warning due to the consequence of contraceptive failure. Patients should consult their healthcare provider about using a reliable barrier method.

Mechanism of Action

How Cefurim Works: Mechanism of Action

The function of Cefurim (Cefuroxime) is defined by its precise, targeted intervention into the structural pathways of susceptible bacterial cells, resulting in bacterial cell lysis. The mechanism operates across two key domains: enzyme inhibition and counter-resistance.

Irreversible Inhibition of Cell Wall Enzymes

This core domain explains the molecular targets and the resulting physiological change. Cefurim acts as an irreversible inhibitor by covalently binding to Penicillin-Binding Proteins (PBPs), the bacterial enzymes responsible for building the structural integrity of the cell wall. This acylation permanently halts the cross-linking of peptidoglycan, initiating a cascade of events that leads to osmotic instability and the rapid destruction of the bacterial cell (bactericidal effect).

Structural Stability Against Bacterial Defenses

This domain describes the intrinsic mechanism of resistance to bacterial enzymes. Cefurim's molecular configuration confers molecular stability, providing inherent resistance against hydrolysis by many common beta-lactamase enzymes produced by bacteria. This stability supports the maintenance of an active drug concentration at the PBP target, which facilitates the process of PBP inhibition and subsequent cell lysis.

Dosage and Administration Information

How to Use Cefurim: Official Administration Guidelines

Cefurim (Cefuroxime) is administered through specific routes and dosing schedules as defined for the medication. The use protocol is structured around the available oral (Axetil) and injectable (Sodium) forms.


Official Routes and Standard Dosing

Cefurim is approved for oral (PO), intravenous (IV), and intramuscular (IM) administration. The frequency is typically twice daily (every 12 hours) for oral forms and three times daily (every 8 hours) for the standard parenteral form.

Route Typical Adult Dosing Range Standard Frequency
Oral (Tablets/Suspension) 250 mg to 500 mg per dose Every 12 hours
Parenteral (IV/IM) 750 mg to 1.5 g per dose Every 8 hours

Treatment courses are typically 7 to 10 days, though the duration for conditions like Early Lyme Disease is 20 days.


Preparation and Special Conditions

Standard administration includes requirements for intake to ensure proper action and absorption:

  • Oral Suspension: Must be taken with food to achieve optimal absorption; the bottle must be vigorously shaken before each use.
  • Oral Tablets: May be taken with or without food and must be swallowed whole (do not crush or chew).
  • Dose Adjustment: Dosage for both oral and parenteral forms must be significantly reduced in adults with marked renal impairment (Creatinine Clearance <30 mL/min) to compensate for slower excretion.

If a dose is missed, the guidance is to take it as soon as remembered, unless it is nearly time for the next dose, in which case the missed dose should be skipped; doses should not be doubled to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefurim

Evidence for Use in Acute Respiratory Infections and Throat Conditions

Research exploring Cefurim was studied in conditions like pneumonia and acute flare-ups of chronic bronchitis, as well as common infections affecting the sinuses and throat. These investigations have primarily taken the form of Randomized Controlled Trials (RCTs), where Cefurim was compared against other antibiotics or against an inactive treatment.

In these studies, researchers monitored outcomes related to physical discomfort, primarily measuring patient-reported changes in symptoms such as fever, cough, and sputum production to gauge clinical response. They also evaluated bacteriological eradication, which determines if the specific susceptible germ causing the infection was cleared from the body. Studies conducted during periods of increased symptom activity described patterns related to symptom evolution and pathogen clearance rates in the observed patient populations.


Evidence for Use in Urinary Tract and Skin Infections

For uncomplicated urinary tract infections (UTIs), research has consisted of both RCTs and large-scale investigations, often involving women included in studies for symptoms like painful or frequent urination. These studies monitored outcomes reflecting daily functioning, measuring symptom status, which researchers referred to as clinical resolution. Furthermore, researchers also assessed bacteriological cure by performing urine culture tests to determine if the urine became sterile.

Findings from these trials described patterns of symptom resolution and negative urine culture status in the studied populations. Some reports compared Cefurim's short-term outcomes against other oral antibiotics; research describes measurements of clinical resolution that were observed in the comparator groups.


What the Research Indicates Is Still Uncertain about Cefurim

Across the research landscape, a common observation is that follow-up durations were limited, typically covering only the treatment period and a short post-treatment assessment window (e.g., 1 to 4 weeks). This structure means that data for long-term outcomes remain insufficient. Research provides context but not individual predictions about the durability of the clinical response or the frequency of subsequent infection recurrence over extended periods.

A significant limitation is that the consistency of findings was observed to correlate with local pathogen resistance on measured clinical resolution rates, which means research does not determine whether an individual will respond similarly. Comparative evidence is limited regarding outcomes against certain modern, targeted agents.

Key Studies & References

  1. Cefuroxime - StatPearls - NCBI Bookshelf (Review of Indications and Guidelines)
  2. Cefuroxime Induced Drug Eruptions: A Systematic Literature Review (Systematic Review including safety follow-up context)

Frequently Asked Questions (FAQ)

Common questions about Cefurim (FAQ)


Q: How quickly does Cefurim start working after taking it?

Official information indicates that the drug’s active ingredient enters the bloodstream relatively quickly. For example, peak concentrations are typically reached within about 45 minutes following an injection. However, this measurement of drug concentration does not correlate directly to the specific time it takes for a person to notice an improvement in their symptoms (clinical response).


Q: Does Cefurim treat viral infections or only bacterial ones?

Cefurim is an antibiotic, and its function is approved for treating infections that are known or strongly suspected to be caused by susceptible bacteria. Regulatory drug sources explicitly state that antibiotics are not effective against viral infections, such as the common cold or flu.


Q: What is the difference between Cefurim and other antibiotics with 'cef' in the name?

Cefurim's active ingredient, Cefuroxime, is classified as a second-generation cephalosporin. The classification indicates it is part of a large family of drugs often containing 'cef' in their names. Its profile includes a well-established stability against certain bacterial defense enzymes called beta-lactamases.


Q: Why do official documents mention the 'mechanism of action' for Cefurim?

The mechanism of action (how the drug works) is described in official documents to define the function of Cefurim. It is defined as a bactericidal agent, which functions by interfering with the enzymes responsible for building the bacterial cell wall.


Q: Is it normal to feel tired or fatigued when taking Cefurim?

Official safety data lists a general feeling of tiredness or weakness among the less common side effects categories. However, more common effects reported relating to the central nervous system include headache and dizziness.


Q: Can taking Cefurim cause stomach upset or digestive issues?

Yes, official regulatory labeling lists gastrointestinal disturbances as common adverse reactions, including nausea and diarrhea. Severe issues like pseudomembranous colitis (severe diarrhea) are also documented as a rare but serious adverse event.


Q: What should be done if someone misses a scheduled time for Cefurim?

If a dose is missed, regulatory guidance is to take it as soon as it is remembered unless it is nearly time for the next scheduled dose. Official information notes that doses are not intended to be doubled to compensate for a missed one.


Q: Is Cefurim often prescribed for long-term use?

Official dosing guidelines describe typical treatment courses that are short, often ranging from 7 to 10 days. Some specific indications, such as Early Lyme disease, have a longer labeled duration of up to 20 days. Use beyond these defined durations is not typically covered in established regulatory guidelines.


Q: Does Cefurim have any known interactions with birth control pills?

Yes, official labeling includes a warning for a clinically significant potential interaction between Cefurim and combined oral contraceptives (birth control pills). This interaction may reduce the effectiveness of the contraceptive due to a theoretical link to the disruption of the estrogen component.


Q: What does the patient information leaflet say about alcohol consumption while on Cefurim?

Official drug information does not typically include a specific contraindication or explicit warning against consuming alcohol while taking Cefurim. However, common side effects of the drug include nausea and dizziness, which could potentially be worsened by the effects of alcohol.


Q: What are the general expectations about recovery time while on Cefurim?

Patient information from authoritative sources states that individuals should generally begin to feel better during the first few days of Cefurim treatment. It is important that the entire course is completed as prescribed. Specific individual recovery timelines are not predicted in regulatory documents.


Q: Can Cefurim be taken with food, or does it matter?

Official administration instructions vary depending on the product form. The oral tablets may be taken with or without food. However, the oral suspension must be taken with food to achieve the optimal level of absorption into the body.


Q: Is Cefurim safe for people who have kidney issues?

Official documents define a special safety precaution for patients with marked renal impairment (significant kidney issues). Since the drug is primarily eliminated by the kidneys, official documents describe that for these patients, a mandatory dosage adjustment is a necessary consideration to limit the risk of neurotoxicity.


Q: How long after finishing the prescription does Cefurim stay in the body?

Official pharmacological data notes that the drug is removed from the body primarily through urine. In adults with normal kidney function, the elimination half-life is typically 1.4 to 2.4 hours.


Q: Are there age limits for who can use Cefurim?

Eligibility is established for adults and adolescents, as well as pediatric patients aged three months and older for the oral suspension form. Official safety and effectiveness have not been established for infants younger than three months of age.


Q: Is Cefurim known to cause any skin reactions or rashes?

Official documentation reports that skin rash and hives (urticaria) are listed as uncommon side effects. Serious, though rare, skin disorders like Stevens-Johnson Syndrome (SJS) are also documented in the safety profile.


Q: Can Cefurim affect the results of any lab tests?

Yes, regulatory documents note that Cefurim can interfere with certain laboratory tests. This interference includes potentially causing a false-positive result in urine glucose tests that use copper reduction methods and a positive Coombs test.


Q: Does the time of day matter when taking Cefurim?

Official administration instructions specify a necessary frequency, such as every 12 hours (twice daily), to maintain the drug’s effectiveness. However, official guidelines do not specify whether a particular time of day (e.g., morning versus evening) is required.


Q: How does Cefurim affect 'good' bacteria in the body?

Official safety warnings note that, like other antibiotics, the use of Cefurim may result in the overgrowth of non-susceptible microorganisms, such as certain yeasts or bacteria. This is a general effect related to the disruption of the body's natural balance of bacteria.


Q: Is it possible to become resistant to Cefurim over time?

Regulatory documents explicitly warn that the misuse or premature discontinuation of Cefurim can contribute to the development of drug-resistant bacteria. This outcome means the medicine may no longer be effective against future infections.


Q: What kind of research has been done on Cefurim's use in children?

Official safety profiles note that the safety of Cefurim in children is generally consistent with that of adults. Clinical studies support its use in pediatric patients (3 months and older) for conditions such as Acute Bacterial Otitis Media and Acute Bacterial Sinusitis.


Q: Is Cefurim ever used to prevent infections before surgery?

Yes, Cefurim is approved for preoperative prophylactic administration, specifically the injectable form. This means it is used to prevent the growth of susceptible bacteria to reduce the incidence of certain infections that can occur after a surgical procedure.


Q: What is the safety profile of Cefurim during pregnancy?

Official labeling restricts the use of Cefurim during pregnancy. It is permitted only when a doctor determines that the likely benefit clearly outweighs the potential risks, primarily due to limited human data regarding its effects.


Q: Does Cefurim interact with any diabetes medications?

Official warnings note that the oral suspension formulation contains sucrose (sugar). Therefore, the total sucrose content must be taken into account when providing advice to patients who are managing diabetes.


Q: Why do some people need to take Cefurim for a longer time than others?

Official guidelines show that the required duration of Cefurim treatment depends entirely on the specific infection being treated. For example, common uncomplicated infections may require a shorter course, while a condition like Early Lyme disease has a longer labeled course of 20 days.


Q: Can Cefurim cause changes in mood or sleep patterns?

Official safety data lists Uncommon side effects related to the nervous system, including sleepiness (somnolence) and hyperactivity. However, the labeling does not generally characterize the effect as a change in 'mood or sleep patterns'.


Q: Is Cefurim considered safe for the elderly population?

Regulatory data notes that Cefurim’s clearance (how quickly it is removed) can be prolonged in elderly patients who have reduced kidney function. Because of this, monitoring kidney function may be necessary to determine if a dose modification is required for some elderly patients.


Q: Is there a maximum time someone can be on Cefurim?

Official guidelines define the maximum labeled duration based on the specific condition being treated, with the longest duration typically being 20 days for certain conditions. A general, absolute maximum time for all uses is not specified in regulatory labeling.


Q: Does Cefurim interact with any heart or blood pressure medications?

While Cefurim is not commonly listed for specific drug-to-drug interactions with heart medications, the parenteral (injectable) formulation contains a significant amount of sodium per dose. This sodium content must be considered for patients with conditions like congestive heart failure or hypertension.


Q: What happens if Cefurim is taken incorrectly (e.g., stopping early)?

Official patient information states that stopping Cefurim too soon or skipping doses may result in the infection not being completely treated. Furthermore, premature cessation increases the risk that the remaining bacteria will become resistant to the antibiotic.


Q: Is Cefurim known to affect a person's ability to drive?

The regulatory documents note that Cefurim can cause side effects such as dizziness or sleepiness (somnolence), and they include specific safety warnings related to driving or operating machinery.

How should Cefurim be stored and disposed of?

How to Store and Dispose of Cefurim (Cefuroxime Axetil)

The official labeling defines specific conditions for storing Cefurim to ensure stability, with rules varying by product form.

Required Storage Conditions

Product Form Temperature Range Container Requirements
Tablets 20^circC to 25^circC (Controlled Room Temperature) Store out of the reach of children.
Oral Suspension (Reconstituted) 2^circC to 8^circC (Refrigeration) Must be kept tightly closed and in the original container.

The reconstituted liquid suspension is stable for 10 days when continuously refrigerated and must be discarded thereafter. All forms of the medicine must be stored out of the reach of children.

Disposal Instructions

Unused or expired Cefurim must be disposed of strictly according to local requirements and pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefurim found in:

A-Z Index: